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Abstract Upon ingestion ethylene glycol (EG, mono-
ethylene glycol) is rapidly absorbed from the gastro-
intestinal tract, and depending on the severity of
exposure signs of toxicity may progress through three
stages. Neurological eﬀects characterize the ﬁrst step
consisting of central nervous depression (intoxication,
lethargy, seizures, and coma). The second stage, usually
12–24 h after ingestion, is characterized by metabolic
acidosis due to the accumulation of acidic metabolites of
EG, primarily glycolic acid (GA), contributing to the
ensuing osmolal and anion gaps. Stage 3, generally 24–
72 h after ingestion, is determined mainly by oxalic acid
excretion, nephropathy, and eventual renal failure. Be-
cause the toxicity of EG is mediated principally through
its metabolites, adequate analytical methods are essen-
tial to provide the information necessary for diagnosis
and therapeutic management. The severe metabolic
acidosis and multiple organ failure caused by ingestion
of high doses of EG is a medical emergency that usually
requires immediate measures to support respiration,
correct the electrolyte imbalance, and initiate hemodi-
alysis. Since metabolic acidosis is not speciﬁc to EG,
whenever EG intoxication is suspected, every eﬀort
should be made to determine EG as well as its major
metabolite GA in plasma to conﬁrm the diagnosis and to
institute special treatment without delay. A number of
speciﬁc and sensitive analytical methods (GC, GC-MS,
or HPLC) are available for this purpose. Due to the
rapid metabolism of EG, the plasma concentration of
GA may be higher than that of EG already upon
admission. As toxicity is largely a consequence of
metabolism of EG to GA and oxalic acid, the simulta-
neous quantiﬁcation of EG and GA is important. For-
mation of calcium oxalate monohydrate in the urine
may be a useful indicator of developing oxalate
nephrosis although urine crystals can result without re-
nal injury. The pathways involved in the metabolism of
EG are qualitatively similar in humans and laboratory
animals, although quantitative diﬀerences have been
reported. Comparison between species is diﬃcult, how-
ever, because the information on humans is derived
mainly from acute poisoning cases whereas the eﬀects of
repeated exposures have been investigated in animal
experiments. Based on published data the minimum
human lethal dose of EG has been estimated at approx.
100 ml for a 70-kg adult or 1.6 g/kg body weight (cal-
culation of dose in ml/kg to mg/kg based in EG den-
sity=1.11 g/l). However, human data from case reports
are generally insuﬃcient for the determination of a clear
dose-response relationship and quantiﬁcation of
threshold doses for systemic toxicity, in particular renal
eﬀects, is limited. As toxicity is largely a consequence of
metabolism of EG to GA, it is important to note that no
signs of renal injury have developed at initial plasma
glycolate concentrations of up to 10.1 mM (76.7 mg/dl).
Plasma EG levels of 3.2 mM (20 mg/dl) are considered
the threshold of toxicity for systemic exposure, if ther-
apeutic strategy is based on the EG concentration alone.
Keywords Ethylene glycol Æ Glycolic acid Æ Analysis Æ
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Introduction
Although ethylene glycol (EG) poisoning is uncommon
in medical practice, it is an important condition to rec-
ognize because early diagnosis and appropriate thera-
peutic intervention can prevent severe morbidity and
mortality. Individuals may consume EG accidentally or
intentionally, usually in the form of antifreeze products
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or as an ethanol substitute. The conditions of exposure
are often diﬃcult to ascertain, as case reports of EG
poisoning are deﬁcient in many areas. Only a minority of
cases include an estimate of the oral intake and the time
course of development of toxic symptoms. The presence
of metabolites, essential for causal therapy, is often
insuﬃciently described. This applies particularly to gly-
colic acid (GA), the only toxic metabolite that accu-
mulates to any extent in human plasma. The level of GA
directly relates to increased anion gap, severity of
symptoms and mortality. Moreover, the plasma con-
centrations of EG and GA are dependent on time from
poisoning to admission and analysis, as well as on
simultaneous ingestion of ethanol, antidote treatment
(ethanol, fomepizole) or institution of hemodialysis.
Misidentiﬁcation of EG has occurred in several clin-
ical cases, for example, with 2,3-butanediol (Jones et al.
1991) and propionic acid arising from inborn meth-
ylmalonic acidemia (Shoemaker et al. 1992). Similarly,
interference between GA and plasma lactate has been
reported in an enzyme-based assay (Porter et al. 2000).
In order to appreciate the importance of selective assays
for the determination of EG and GA for both diagnosis
and therapeutic intervention based on toxicokinetic
considerations, the analytical methods are reviewed in
the ﬁrst instance. The data obtained in cases of EG
poisoning are then related to the occurrence of systemic
toxicity, especially nephrotoxicity, and its possible dose-
response relationship.
Analytical methods
EG is commonly analyzed after derivatization by gas
chromatography (GC) using either a ﬂame ionization
detector or mass spectrometry (MS) for quantiﬁcation.
The metabolites of EG, glycolic acid in particular, are
determined in body ﬂuids by high-performance liquid
chromatography (HPLC), GC, or GC-MS. Selected
methods for EG and glycolic acid are summarized in
Tables 1 and 2, respectively. The presently preferred
method for determination of EG by GC is based on
phenylboronation (Hewlett et al. 1986; Porter and Au-
ansakul 1982). When the analysis is performed with a
commonly used capillary column, it appears to be free
from known interferences (Porter et al. 1994). Other
methods such as those based on direct injection may be
subject to carryover (Aarstad et al. 1993) or signiﬁcant
interferences from physiological substances, for exam-
ple, propionic acid (present in methylmalonic acidema;
Shoemaker et al. 1992) and 2,3-butanediol (present in
serum from alcoholic patients; Jones et al. 1991).
For the rapid determination of EG an enzymatic
method using glycerol dehydrogenase has been proposed
(Hansson and Masson 1989). However, interferences
with the enzymatic assay are to be expected from glyc-
erol or propylene glycol (used as solvents for parenteral
drugs) or b-hydroxybutyrate (present in serum from
patients with diabetic ketoacidosis; Allen and Hamlin T
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1993; Blandford and Desjardins 1994; Malandain and
Cano 1995; Nilsson and Jones 1992).
Determination of GA by HPLC-MC (Hewlett et al.
1983; Petrarulo et al. 1991) involves complex and rather
laborious methodology. Other methods based on isota-
chophoresis (Øvrebø et al. 1987) or on ion chromatog-
raphy (Hagen et al. 1993) are not available in many
laboratories. An enzymatic method using glycolate oxi-
dase (Kasidas and Rose 1979) is not speciﬁc due to
lactate interference.
More recently a GC procedure with ﬂame ionization
detection for the simultaneous determination of EG and
GA in serum has been proposed that appears suitable
for clinical use (Yao and Porter 1996). The method,
based on trimethylsilylation of EG, glycolic acid or 3-
bromo-1-propanol (internal standard), has a high assay
precision and is virtually free of interferences. Of more
than 60 potentially interfering compounds for which
retention times of their trimethylsilyl derivatives have
been determined only 3-dimethyl-amino-1-propanol
partly overlapped with EG and 1,2-butanediol coeluted
with GA. Neither of these compounds is naturally
occurring or present in medications. The same labora-
tory recently reported an adaptation of this procedure
using the more speciﬁc mass spectral detection instead of
ﬂame ionization detection (Porter et al. 1999). In this
procedure EG and GA are speciﬁcally analyzed as the t-
butyldimethylsilyl derivatives. These derivatives are
more stable than the trimethylsilyl derivatives, have
better GC resolution and they have more characteristic
mass spectra.
In other GC methods GA is derivatized to methyl-
glycolate and analyzed using methyl propionate as
internal standard (Fraser and MacNeil 1993; Moreau
et al. 1998). The limit of quantitation of GA by GC
analysis was 0.33 mM with a mean conﬁdence value of
7% and recovery from plasma that was practically
complete (Moreau et al. 1998).
The selectivity and sensitivity of GA analyses in hu-
man poisoning cases reported in the recent literature has
been evaluated (Bartels 2002). In spite of the variety of
methods used the determination of GA in plasma/serum
was fairly accurate. The highly speciﬁc GC-MS assays
generally provided conﬁrmation of the analytical results
with another method. The detection limit for GA by the
various assays ranged from 0.05–7 mM, with most be-
tween 0.13–2.8 mM (1.0–21.3 mg/dl). This level of sen-
sitivity is generally well below the levels of GA reported
in such cases (see also Table 4).
It is noted that only a few clinical toxicology labo-
ratories routinely oﬀer such measurements. In the acute
setting of managing the intoxicated patient the use of
serum EG (determined enzymatically or with an auto-
mated analyzer), anion, and osmolal gaps coupled with
arterial blood gas measurements and urinalysis are
expected to provide the greatest diagnostic yield within
an acceptably short time period (Wolf and Shaw 1998).
Recent national survey in the United States found that
only 25% of 95 teaching hospitals perform EG deter-T
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minations with a median turnaround time of 1.5 h,
whereas if the test is sent out, the time is 42 h (Kearney
et al. 1997).
Toxicokinetics and metabolism of ethylene glycol
To understand the relevance of glycolic acid levels and
their bearing on the course of EG intoxication it is
important to discuss the toxicokinetics and metabolism
of EG in regard to prime parameters indicative of met-
abolic and organ damage. EG is rapidly absorbed from
the gastrointestinal tract and metabolized. Its half-life in
plasma is estimated at 3–7 h in laboratory animals
(Marshall 1982; Winek et al. 1978) and appears to be of
a similar order in humans. Upon self-administration of
8, 10, and 12 ml EG by a male volunteer, serum t1/2 was
4.5 h with 2.3% of the dose eliminated in the urine as
oxalic acid (Reif 1950). Data on toxicokinetic parame-
ters for EG compiled from the more recent literature are
consistent with t1/2 of 3–8.6 h, Vd 0.5–0.8 l/kg, and mean
renal clearance between 0.75 ml/min (renal failure) and
27.5 ml/min (normal renal function; Eder et al. 1998). In
general the ratio of urinary to serum EG concentration
is high, and renal clearance values of 17–70 ml/min have
been reported (Cheng et al. 1987; Harry et al. 1994).
EG is ﬁrst metabolized to glycolaldehyde by hepatic
alcohol dehydrogenase, then to GA via aldehyde dehy-
drogenase. GA is subsequently oxidized to glyoxylic acid
and then oxalic acid (Fig. 1). Further suggested path-
ways in humans involve the conversion of glycolalde-
hyde to glyoxal, glyoxylate to glycine (and its conjugate
hippurate in the presence of benzoic acid) and, theo-
retically, to formic acid (Gabow et al. 1986). The
metabolites may independently cause toxicity in labo-
ratory animals (Bove 1966). However, GA is the only
toxic metabolite that accumulates to any extent in the
plasma of monkeys (Clay and Murphy 1977) and rats
(Chou and Richardson 1978) as well as in humans poi-
soned with EG (Jacobsen et al. 1984). Thus both
experimental and human studies indicate that GA
metabolism to glyoxylate is rate-limiting in the meta-
bolic pathway of EG (Moreau et al. 1998). In contrast,
both glycolaldehyde and glyoxylate have very short half-
lives (Chou and Richardson 1978; McChesney et al.
1972), the former being oxidized to GA, while glyoxylic
acid is metabolized via diverse pathways to oxalic acid,
hippuric acid (via glycine) or possibly other metabolites.
Because of its rapid metabolism EG may be low or
undetectable in plasma/serum while GA attains high
levels (Fraser and MacNeil 1993; Hewlett et al. 1986).
The elimination half-life of EG is increased more than
tenfold in the presence of ethanol because both com-
pounds compete for the active site of alcohol dehydro-
genase (Eder et al. 1998; Jacobsen et al. 1988). This
enzyme has a much greater aﬃnity for ethanol than for
EG and concentrations of ethanol as low as 11 mM
(50 mg/dl) saturate the enzyme (Peterson et al. 1981).
Because of the high capacity of alcohol dehydrogenase
to oxidize EG in the absence of a competitive inhibitor
the measurement of GA in addition to that of EG is
important for diagnosis and therapy of intoxication. In
fact the serum concentration of GA has been shown to
be correlated more closely with the clinical symptoms
than the concentration of EG (Hewlett et al. 1986).
The elimination kinetics of EG in human subjects was
analyzed in the context of establishing the eﬃcacy of
alcohol dehydrogenase inhibition (Sivilotti et al. 2000).
In 19 patients with EG concentrations of 0.56–
34.03 mM, elimination of EG was ﬁrst order during
fomepizole (4-methyl pyrazole) monotherapy (t1/2
19.7±1.3 h) and under these conditions was not aﬀected
by the presence of ethanol. The elimination rate was
signiﬁcantly faster (t1/2 <8.6±1.1 h) in the absence of
fomepizole and ethanol. EG elimination by the kidneys
was proportional to the renal function as estimated by
creatinine clearance with a fractional excretion of
25.5±9.4%. All patients with normal serum creatinine
concentration at the initiation of fomepizole treatment
had rapid rates of renal elimination (t1/2 16.8±0.8 h).
Thus renal elimination and/or hemodialysis were the
only signiﬁcant routes of EG elimination as long as
fomepizole concentration was maintained above 10 lM
(EG/fomepizole ratio <100:1).
GA is converted to glyoxylate (Chou and Richardson
1978; McChesney et al. 1972). This being the rate lim-
iting step and because of its rapid formation from EG,
GA may accumulate in the plasma. Moreover, the
pathway from glyoxylic acid to formic acid is practically
absent in humans and only small amounts of GA appear
Fig. 1 Metabolism of ethylene glycol. Bold arrows indicate the
major pathway
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as oxalic acid (about 1%) or glycine/benzoic acid in the
urine. The calculated volume of distribution of GA is
low (0.55 l/kg; Moreau et al. 1998), similar to that of
EG. This indicates that the substances remain in the
vascular compartment. Both EG and its main metabolite
GA are eﬀectively removed by hemodialysis (Jacobsen
et al. 1984).
A number of case reports refer to the elimination
kinetics of GA following EG poisoning. In ten patients
the endogenous elimination rate of glycolate was
1.08±0.67 mmol/l per hour and elimination t1/2 was
10.43±7.90 h (n=4). The elimination t1/2 during dialy-
sis was reduced to 2.58±0.70 h (n=8), and hemodialysis
(n=5) cleared GA at a rate of 10.20±1.38 l/h with ﬂow
rates 15–24 l/h (Moreau et al. 1998).
Considerations of interspecies diﬀerences are
important whenever animal data are extrapolated to
man. The elimination half-life for EG in rats at doses
from 20-2,000 mg/kg body weight ranges from 1.0–
2.5 h (Frantz et al. 1996a, 1996b; Hewlett et al. 1986),
while that in acutely intoxicated humans ranges from
3.0 to 8.4 h (Jacobsen et al. 1988; Peterson et al. 1981).
In rats the blood levels of GA, the ﬁrst identiﬁed
metabolite of EG using GC-MS technique, increased
nearly proportionally to the oral dose from 10 to
150 mg/kg EG but increased disproportionately from
500 to 1000 mg/kg EG (Pottenger et al. 2001). EG and
GA were dose-dependently eliminated in the urine for
doses of 500 mg/kg EG and above. This high-dose ef-
fect was probably due to saturation of metabolic con-
version of GA to downstream metabolites. Thus the
degree of GA accumulation is likely related to GA
metabolism to glyoxylate and this rate-limiting step
may diﬀer among species.
In fact Booth et al. (2004) have shown using in vitro
techniques that metabolism of [1,2-14C]EG by rat liver
slices results in higher levels of GA than produced by
liver slices from rabbits or humans. With human liver
the formation of low level GA was detected in one
incubation of slices from one of four donors but only at
one extended time point. Glyoxylate was detected with
liver slices from all four humans. Human liver tissue was
the most eﬀective at metabolizing GA to glyoxylic acid.
The ratios of Vmax/Km representing the relative clearance
of GA from liver tissue, were approximately 14:9:1 for
human, rat, and rabbit liver, respectively. These in vitro
data suggest that humans are more eﬀective at metab-
olism of GA to glyoxylic acid than rats or rabbits.
Consequently there is less chance for the accumulation
of the toxic metabolite GA in humans than in these
laboratory animals.
Ethylene glycol poisoning
Accidental or intentional ingestion of sweet tasting EG
may occur in adults and in children. In 1996 the
American Association of Poison Control Centers re-
corded 5,548 reports of EG ingestion, 17 of which
related to fatalities as a result of suicide or intentional
ingestion. About 18% of the reports involved children
younger than 6 years (Litovitz et al. 1997). The ingestion
of EG may result in inebriating eﬀects followed by se-
vere central nervous system depression, cardiopulmo-
nary failure, acute renal failure, metabolic acidosis, and
possibly death (Beasley and Buck 1980). The metabolic
acidosis and severe toxicity are the consequence of the
metabolism of EG to several organic acids, among
which GA is the principal toxic metabolite that accu-
mulates in blood (Gabow et al. 1986; Jacobsen et al.
1984). Rapid and accurate identiﬁcation of EG or its
metabolites is necessary not only for early diagnosis and
successful therapy but also to exclude other possible
causes of increased anion gap metabolic acidosis (Eder
et al. 1998).
Numerous case reports are available on deliberate
ingestion of EG but very few report accidental ingestion
(zero in 1996, according to the American Association of
Poison Control Centers). The information on dose level
is generally insuﬃcient for the determination of a clear
dose-response relationship. From published data the
minimum human lethal dose has been estimated at
approximately 100 ml for a 70-kg adult (about 1.4 ml/
kg, or 1.6 g/kg; Ellenhorn and Barceloux 1988). An
estimate of the human lethal dose of EG based on 42
published fatal cases indicates a range between 30 ml
and 1500 ml (personal communication, W. Gulledge,
letter to Ethylene Oxide/Ethylene Glycol Panel, Ameri-
can Chemistry Council, Arlington, Va., December
2000). However, survival has been reported after inges-
tion of up to 1000 ml (Gaultier et al. 1976).
Clinical signs of systemic toxicity following ingestion
of EG generally progress in three stages. Central nervous
system (CNS) eﬀects are apparent within 0.5–2 h of
ingestion and include inebriation (in the absence of
detectable ethanol), nausea, vomiting, nystagmus, pap-
illary edema, hyporeﬂexia, convulsions, and coma.
Within 12–24 h after ingestion cardiopulmonary mani-
festations are observed, including tachycardia, tachyp-
nea, hypertension, pulmonary edema, and congestive
heart failure. A generally late event is renal insuﬃciency
occurring 24–72 h after ingestion. Neurological eﬀects
suggestive of cranial nerve damage (facial paralysis,
impaired vision) may appear 1–2 weeks after a single
exposure (Hall and Rumack 2001).
The severity of toxicological eﬀects and the progres-
sion from one stage to the next depend on the amount of
EG ingested and the timing of medical intervention
(Eder et al. 1998). However, the lag period between the
stages depends on the time required for the toxic
metabolites of EG to accumulate. Therefore there is a
poor correlation between serum EG concentration and
the clinical course, and death has been reported with
virtually undetectable serum EG concentrations (Lito-
vitz et al. 1997). The systemic eﬀects of poisoning de-
pend primarily on the induction of metabolic acidosis
and the magnitude of the osmolal gap and anion gap,
respectively.
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Serum osmolality is determined from the concentra-
tion of sodium, urea nitrogen, and glucose according to
the formula: [1.86 · sodium (mM) + urea nitrogen
(mM) + glucose (mM)]/0.93=mOsm/kg H2O (Glasser
et al. 1973). In a healthy individual serum osmolality is
270–290 mOsm/kg H2O. An osmolal gap, i.e., the dif-
ference between the actually measured (by freezing point
depression) and calculated osmolality, results from the
presence of other solutes in the serum that are not
considered in this formula. An increase in the osmolal
gap, generally considered important when higher than
10 mOsm/kg H2O, suggests the presence of unmeasured
osmotically active substances such as EG, methanol,
ethanol or acetone (i.e., in diabetic ketoacidosis; Eder
et al. 1998; Hoﬀman et al. 1993). In the case of EG
poisoning the concentration of parent compound ac-
counts for most of the osmolal gap (Jacobsen et al.
1988). Each 16 mM (100 mg/dl) increment in EG con-
centration contributes about 16 mOsm/kg H2O, and
each 22 mM (100 mg/dl) of ethanol contributes
22 mOsm/kg H2O to the osmolal gap. As EG is
metabolized to acidic intermediates, the osmolal gap is
reduced and the anion gap is increased (Jacobsen et al.
1988) because these anions are counterbalanced by so-
dium and thus are considered in calculating the serum
osmolality (Hoﬀman et al. 1993).
The anion gap is the diﬀerence between the sum of
the measured cations and the sum of the measured an-
ions: [(Na++K+)(HCO3+Cl)]. In healthy indi-
viduals the physiological anion gap is 12–16 mM. The
values of this parameter noted in ten patients with EG
intoxication ranged from 20–41 mM (Moreau et al.
1998). Organic acids will increase the anion gap and GA
has been shown to account for 96% or more of the
anion gap in patients poisoned with EG (Gabow et al.
1986; Jacobsen et al. 1984). In fact the initial anion gap
is well correlated with initial serum GA (R2=0.65,
P=0.005; Moreau et al. 1998). Although the presence of
metabolic acidosis with an increased anion and osmolal
gap is suggestive of EG poisoning, it is not a speciﬁc
diagnosis. It may be present in methanol poisoning
(Jacobsen et al. 1982), alcoholic ketoacidosis (Schelling
et al. 1990), diabetic ketoacidosis (Davidson 1992), renal
failure (Sklar and Linas 1983), and multiple organ fail-
ure (Inaba et al. 1987).
Nephrotoxicity
Mode of action of renal eﬀects
Data from human poisoning cases and repeated-dose
toxicity studies in experimental animals indicate that the
kidney is a critical organ for the toxicity of EG. Meta-
bolic acidosis and degenerative changes in the kidney
(including tubular degeneration with deposition of cal-
cium oxalate) have consistently been observed in a range
of species (CICAD 2002). In addition to the adverse
eﬀect of metabolic acidosis on renal function, due
mainly to GA accumulation, oxalic acid is of particular
toxicological signiﬁcance, although it is only a minor
metabolite of EG. Oxalic acid chelates with calcium ions
resulting in the deposition of insoluble calcium oxalate
crystals in tissues, notably in the kidney. Crystals of
calcium oxalate monohydrate and dihydrate precipitate
in the proximal convoluted tubules and renal interstitial
tissue, whereby the dihydrate is formed only at high
concentrations of calcium and oxalate (Burns and Fin-
layson 1980). Calcium oxalate crystals are considered to
be closely associated with the nephropathy developing in
delayed cases of EG poisoning (Jacobsen and McMartin
1986; Wiley 1999). Calcium oxalosis may explain the
hypocalcemia that is often observed in EG poisoning
(Jacobsen et al. 1988).
The histological diagnosis of acute renal failure sec-
ondary to EG poisoning depends on the recognition of
tubular damage (vacuolar changes predominantly of the
proximal tubular epithelium) in association with intra-
tubular birefringent oxalate crystals. In the urine cal-
cium oxalate may be excreted not only as dihydrate
(octahedral) crystals but also, characteristically, as
monohydrate (needle shaped) crystals. The latter are
strongly birefringent and may thus be distinguished
from hippuric acid crystals (Eder et al. 1998). Recogni-
tion of monohydrate calcium oxalate crystals in the ur-
ine facilitates rapid diagnosis of EG ingestion (Terlinski
et al. 1981). Thus crystalluria, identiﬁed by simple
microscopy of the urine, is an important and rather
speciﬁc diagnostic tool and repeated urinalysis is very
useful in the diﬀerential diagnosis of an anion gap
metabolic acidosis of unknown origin (Jacobsen et al.
1988). In experimental animals, EG-associated renal
damage has been observed only at doses greater than
those at which there were increases in crystalluria (De-
Pass et al. 1986).
Dose response
Information on the dose-response relationship has been
obtained in laboratory animals. In relevant studies
quoted in the CICAD (2002) document, the no observed
adverse eﬀect level (NOAEL) for renal eﬀects of EG in
the most sensitive animal species (male rat) was deter-
mined to be a daily oral dose of 200 mg/kg in a pivotal
chronic 2-year bioassay (DePass et al. 1986). In a sub-
chronic 13-week study the NOAEL corresponded to an
approximate daily intake of 400 mg/kg (Robinson et al.
1990). In an unpublished 16-week subchronic study
(Gaunt et al. 1974, quoted in CICAD 2002), the inci-
dence of individual nephrons with degenerative changes
was not statistically diﬀerent from controls up to and
including a daily dose of 180 mg/kg. At a daily dose of
715 mg/kg signiﬁcant treatment-related renal eﬀects
occurred, including increased kidney weight, increased
water consumption, and urine oxalate excretion. In a
recent comparative oral (dietary) toxicity study of
16 weeks duration conducted in male Wistar and F-344
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rats EG produced crystal nephropathy at daily dose
levels of 1000 and 500 mg/kg. The NOAEL in this study
was 150 mg/kg per day for both strains (Mertens 2002).
Pharmacokinetic and metabolism data referred to
above indicate that humans may be less sensitive than
rodents to the ingestion of EG. However, data on dose-
response in humans are virtually absent since kinetic
variables have been measured primarily in poisoned
individuals. In the absence of suﬃcient human data dose
response may be characterized by animal data. This
appears to be feasible on the basis of renal eﬀects that
were typically observed in rats. In a 2-year bioassay a
daily oral dose of 200 mg/kg has been determined as the
NOAEL (DePass et al. 1986). In the CICAD (2002)
document a tolerable intake for EG, with regard to the
development of histopathological changes in the kidney
of male rats, has been derived from Gaunt et al. (1974)
based on a benchmark dose05 (BMD05, the dose esti-
mated to cause a 5% increase in incidence over the
background response rate, calculated according to
Howe 1995). A tolerable intake of 0.05 mg/kg body
weight per day for EG was based on a BMD of 49 mg/
kg per day calculated for the presumed development of
renal eﬀects in animals and an uncertainty factor of
1000. However, this tolerable intake was uncertain,
owing primarily to lack of information on progression of
renal lesions in the most sensitive animal model. How-
ever, the BMD05 derived from the data of Robinson
et al. (1990) range from 316.4 to 501.9 (95% lower
conﬁdence limit 85.5) to 214.9 mg/kg per day for indi-
vidual lesions. Based on these data a human NOAEL of
about 200 mg/kg per day for kidney eﬀects caused by
oral exposure to EG can be assumed. This estimate is in
good agreement with the NOAEL of 150 mg/kg per day
determined by Mertens (2002). However, caution should
be exerted in directly extrapolating the animal data to
man. Little is known on the pathogenesis of the kidney
lesions and the toxicokinetic information is insuﬃcient
for reliable interspecies comparison.
A cross-sectional study on 33 aviation workers ex-
posed to EG vapor up to 22 mg/m3 or EG mist up to
190 mg/m3 during deicing operations found no evidence
of renal injury (based on urinary albumin, b-N-acetyl-
glucosaminidase, b2-microglobulin and retinal-binding
protein), even with the observation in 16 cases of post-
shift urine samples that contained EG quantities
exceeding 5 mM/M creatinine. Apparently six cases of
these higher urinary levels were from individuals who
did not wear paper-type masks intended to protect their
respiratory passages from exposure to aerosol (mist;
Ge´rin et al. 1997). Assuming continuous exposure and
complete absorption (from the respiratory tract and/or
skin which is overly conservative), exposure to 22 mg/m3
vapor and 190 mg/m3 aerosol could have resulted in
daily systemic exposure to 3.14 mg/kg EG from vapor
or 27.14 mg/kg EG from aerosol in a 70-kg worker
breathing 10 m3 of air during an 8-h shift.
The putative toxic metabolite in the induction of
kidney lesions, oxalic acid, is derived from glyoxylic
acid, a further metabolite of GA. There are no com-
parative kinetic data that can serve as a basis for inter-
species scaling to explain possible quantitative
diﬀerences between humans and rats in the formation
and excretion of these metabolites. However, Booth
et al. (2004) showed that when using whole liver slice
incubations human tissue metabolizes GA more rapidly
than rat and rabbit tissue, and that in the human liver
slices GA is not detectable following exposures of up to
40 mM EG. The failure to detect GA could be attributed
to its eﬀective further metabolism to glyoxylic acid. In
principle, glyoxylic acid could also be formed from
glyoxal (Fig. 1), but glyoxal was not detected in the
human liver slice incubations.
Evidence from a recent follow-up study of 19 con-
secutive patients with conﬁrmed EG poisoning (Brent
et al. 1999) indicated that no signs of renal injury
developed in any patient whose initial plasma GA con-
centration did not exceed 10.1 mM (76.8 mg/dl) or
whose serum creatinine concentration was normal. All
of the patients in whom renal injury developed had
plasma GA concentrations of 12.9 mM or higher
(‡98.0 mg/dl). The respective baseline values obtained in
these patients prior to fomepizole treatment are given in
Table 3. Renal injury was independent of the initial
plasma EG concentration, but all patients who had
plasma EG concentrations in excess of 8.1 mM (50 mg/
dl) underwent hemodialysis. The ratio of urinary to
serum EG concentrations is high, and renal EG clear-
Table 3 Baseline characteristics of 19 patients with ethylene glycol poisoning: mean values (range) (Brent et al. 1999)
Characteristic All patients (n=19) Patients with renal
injury (n=9)
Patients without renal
injury (n=10)
Pa
Sex: M/F 17/2 8/1 9/1 –
Age (years) 41 (19–73) 43 (28–60) 40 (19–73) –
Time from EG ingestion to
treatment with fomepizole (h)
11.4 (6.6–20.8) 15.1 (9.0–20.8) 9.6 (6.6–13.9) –
Plasma ethylene glycol (mM) 19.8 (3.9–71.9) 15.9 (3.9–34.4) 23.2 (4.2–71.8) 0.34
Plasma glycolic acid (mM) 11.8 (0-34.8) 21.0 (12.9–343.9) 3.7 (0–10.1) <0.001
Serum creatinine (mM) 132.6 (53.0–291.7) 194.5 (132.6–291.7) 79.6 (53.0–106.1) <0.001
Arterial pH 7.24 (6.93–7.47) 7.14 (6.93–7.35) 7.34 (7.16–7.47) 0.003
Serum bicarbonate (mM) 12.9 (4.0–28.0) 6.8 (4.0–9.8) 17.8 (5.0–28.0) <0.001
aFor comparison between patients with and without renal injury; mean values compared by Student’s unpaired t test.
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ance values of 17–70 ml/min are reported. After the
initiation of fomepizole treatment, urinary oxalate
excretion markedly decreased due to the reduced overall
EG metabolism, irrespective of whether signs of renal
injury were present.
Estimates of systemic exposure from case reports
Because of the relatively rapid metabolism of EG
patients may present with low levels of EG but with
signiﬁcant plasma concentrations of GA, and such a
presentation is more likely at longer periods between EG
ingestion and blood analysis (except in the case of
coingestion of ethanol which would inhibit the metab-
olism of EG). The data analysis of EG poisoning cases is
generally limited due to the unknown amounts ingested,
failure to analyze EG early (prior to GA formation),
insuﬃcient information on the kinetics of endogenous
elimination, and the eﬀects of treatment measures.
Table 4 summarizes a number of case reports that
contain measurements of systemic exposure considered
to be analytically reliable. Emphasis is on initial pre-
sentation rather than on the clinical monitoring under
treatment. There is no consistent ratio between EG and
GA concentrations as early as admission due to the
variable periods between EG ingestion and serum
analysis. As a consequence measurements of EG alone
would inadequately reﬂect the severity of initial intoxi-
cation and are not suited to establish a no-eﬀect level or
deﬁne a potentially toxic level of exposure. Patients re-
ported to have presented with high levels of EG (up to
55.3 mM) and GA below detection limit exemplify this
statement. These patients had ethanol present in serum
at the time of admission, explaining both the absence of
GA and of signiﬁcant symptoms (Porter et al. 1999). On
the other hand, if therapeutic strategy is based on the
EG concentration, appropriate measures (ethanol or
fomepizole) are generally recommended at plasma EG
levels higher than 3.2 mM (>20 mg/dl; Porter et al.
1999). This value is considered the threshold of toxicity
for systemic exposure, including renal failure.
Reliable information is lacking in most cases of EG
intoxication regarding the amounts ingested, and due to
the complex toxicokinetics and lack of an appropriate
physiologically based pharmacokinetic model the ana-
lytical data obtained on admission are insuﬃcient for
back-calculation of dose levels. Notwithstanding these
diﬃculties, the data presented in Table 4 suggest that
exposures much higher than the estimated threshold of
3.2 mM favorably respond to therapeutic intervention.
Conclusion
The available data on human exposures to EG refer
largely to acute poisoning cases, and therefore their
value for the assessment of dose-response is limited.
Despite this circumstance the literature base is consistent T
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in the estimate of the minimum lethal dose in humans at
about 1600 mg/kg body weight. Tolerable levels of in-
gested EG are derived from animal data. They indicate a
NOAEL of approx. 200 mg/kg body weight/day for
nephrotoxicity as critical endpoint. Aircraft de-icing
workers systemically exposed to an estimated 27 mg/kg
EG did not demonstrate any kidney (or other) eﬀects.
GA, the only toxic metabolite that occurs to any
extent in human plasma, mainly determines the toxicity
of EG. Case reports suggest that a plasma GA concen-
tration of about 10 mM (76 mg/dl) does not cause
nephrotoxicity in humans. On the other hand, plasma
EG levels of about 3.2 mM (20 mg/dl) are considered a
threshold of toxicity for systemic exposure to EG. Be-
cause the severity of EG toxicity is more closely corre-
lated with the plasma concentration of GA than with
that of EG, the simultaneous determination of both
parameters is important for diagnosis and therapeutic
management. Analytical methods appropriate for this
purpose are reviewed. Although animal data are used in
comparative toxicokinetics, they cannot be extrapolated
directly to predict human response. Studies in vitro
demonstrated human liver to be more eﬀective at further
metabolizing GA than liver from rats or rabbits, sug-
gesting that humans would accumulate less GA than
laboratory animals following exposure to similar
amounts of EG.
There appears to be suﬃcient evidence from human
and animal data that tolerable levels of EG exposure
exist. However, this consideration should not detract
from initiating appropriate preventive or therapeutic
measures.
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